vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1814-6023-2025-22-2-169-176vestim-1033Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEОптимальные условия хранения образцов крови для оценки гемосовместимости медицинских изделий in vitroOptimal conditions for storing blood samples for assessing the hemocompatibility of medical devices in vitrohttps://orcid.org/0009-0009-0312-3982ЛаппоЛ. Г.LappoL. G.

Лаппо Лидия Геннадьевна – науч. сотрудник.

Ул. Академическая, 8, 220012, Минск

Lidziya G. Lappo ‒ Researcher.

8, Akademicheskaya Str., 220012, Minsk

lida_lappo@bk.ruhttps://orcid.org/0000-0002-5493-9799СычикС. И.SychikS. I.

Сычик Сергей Иванович ‒ канд. мед. наук, доцент, директор.

Ул. Академическая, 8, 220012, Минск

Sergey I. Sychik ‒ Ph. D. (Med.), Associate Professor, Director.

8, Akademicheskaya Str., 220012, Minsk

rspch@rspch.byhttps://orcid.org/0000-0002-4119-1793ГрынчакВ. А.HrynchakV. A.

Грынчак Виталий Александрович ‒ канд. мед. наук, заведующий лабораторией.

Ул. Академическая, 8, 220012, Минск

Vitali A. Hrynchak ‒ Ph. D. (Med.), Head of the Laboratory.

8, Akademicheskaya Str., 220012, Minsk

grinchakva@gmail.comНаучно-практический центр гигиеныScientific and Practical Center of Hygiene202528052025222169176Copyright © Лаппо Л.Г., Сычик С.И., Грынчак В.А., 20252025Лаппо Л.Г., Сычик С.И., Грынчак В.А.Lappo L.G., Sychik S.I., Hrynchak V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/1033

Цель работы – оптимизация и стандартизация условий хранения цельной гепаринизированной крови человека до ее запуска в динамические in vitro тест-системы искусственного кровотока для оценки гемосовместимости медицинских изделий.

Для проведения исследования забор крови у доноров осуществлялся в объеме 150 мл с использованием иглыбабочки с луер-адаптером, катетера и шприца, заполненного гепарином (1,5 МЕ/мл). В дальнейшем гепаринизированную кровь переносили в пробирки и выдерживали в термостате при температурах 20, 25, 30 и 37 oC на протяжении 40, 50 и 60 мин, моделируя комнатную температуру и температуру тела человека. В качестве контрольного образца использовали цельную кровь, полученную сразу после ее забора у доноров, с добавлением гепарина. Для определения влияния времени и температуры хранения крови на ее активацию был изучен ряд гематологических и иммуноферментных показателей.

Хранение цельной крови при комнатной температуре инициировало активацию тромбоцитов и коагуляционных механизмов через 60 мин. Влияние повышенных температур 30 и 37 oC характеризовалось статистически значимым увеличением таких показателей, как бета-тромбоглобулин (в 2,2–2,3 раза), тромбоксан B2 (в 2,0–2,1 раза), протромбин F1+2 (в 1,6–1,8 раза) и тромбин-антитромбиновый комплекс III (в 1,8–2,0 раза), уже через 40 мин хранения.

Экспериментально установлено, что для оценки гемосовместимости медицинских изделий с оптимальными условиями хранения цельной гепаринизированной крови человека являются время хранения не более 50 мин и комнатная температура 20–25 oC. Полученные данные будут способствовать повышению надежности оценки совместимости медицинских изделий с кровью и, как следствие, снижению риска развития неблагоприятных последствий для пациентов.

The purpose of the work is to establish optimal storage conditions for heparinized human whole blood before launching it into dynamic in vitro test systems of artificial blood flow to assess the hemocompatibility of medical devices.

To conduct the study, blood was collected from donors in a volume of 150 ml using a butterfly needle with a luer-adapter, a catheter and a syringe filled with heparin (1.5 IU/ml). Subsequently, heparinized blood was transferred into test tubes and kept in a thermostat at temperatures of 20, 25, 30 and 37 oC for 40, 50 and 60 minutes, simulating room temperature and human body temperature. As a control sample, solid blood obtained immediately after its fence in donors was used, with the addition of heparin. To study the effect of time and temperature of blood storage on its activation, a number of hematological and immunoenzyme parameters were studied.

Storing whole blood at room temperature initiated activation of platelets and coagulation mechanisms within 60 minutes. The effect of elevated temperatures of 30 and 37 oC was characterized by a statistically significant increase in the content of indicators such as beta-thromboglobulin (by 2.2–2.3 times), thromboxane B2 (by 2.0–2.1 times), prothrombin F1+2 (by 1.6– 1.8 times) and thrombin-antithrombin complex III (by 1.8–2.0 times) after 40 minutes of storage.

It was experimentally established that to assess the hem-proposal of medical products with optimal storage conditions for solid heparinized blood of a person is a storage time of not more than 50 minutes and room temperature of 20–25 °C. The data obtained will help improve the reliability of assessing the blood compatibility of medical devices and, as a result, reduce the risk of adverse consequences for patients.

гемосовместимостьусловия хранениямедицинские изделиямаркеры коагуляцииактивация тромбоцитовin vitro тест-системыкровь человекаоценка безопасностиhemocompatibilitystorage conditionsmedical devicescoagulation markersplatelet activationin vitro test-systemshuman bloodsafety assessmentИсследования проведены в рамках ГНТП «Научно-техническое обеспечение качества и доступности медицинских услуг» на 2021–2025 годы (подпрограмма «Безопасность среды обитания человека», задание 04.08. «Разработать метод оценки гемосовместимости in vitro изделий медицинского назначения на основе тест-модели искусственного кровотока»)The research was conducted within the framework of the State Scientific and Technical Program “Scientific and Technical Support for the Quality and Availability of Medical Services” for 2021–2025 (subprogram “Safety of the Human Environment”, task 04.08. “Develop a method for assessing the in vitro hemocompatibility of medical devices based on a test model of artificial blood flow”)ReferencesHemocompatibility testing of blood-contacting implants in a flow loop model mimicking human blood flow / A. Link, G. Cattaneo, E. Brynda [et al.] // Journal of Visualized Experiments. – 2020. – Vol. 157. – P. e60610. https://doi.org/10.3791/60610-vLink A., Cattaneo G., Brynda E., Riedel T., Kucerova J., Schlensak Ch., Wendel H. P., Krajewski S., Michel T. Hemocompatibility testing of blood-contacting implants in a flow loop model mimicking human blood flow. Journal of Visualized Experiments, 2020, vol. 157, p. e60610. https://doi.org/10.3791/60610-vBhatt, A. Product evaluation: blood compatibility studies / A. Bhatt, N. Renjith // Biomedical Product and Materials Evaluation / ed. P. V. Mohanan. – Sawston, Cambridge, 2022. – P. 435–459.Bhatt A., Renjith N. Product evaluation: blood compatibility studies. Biomedical Product and Materials Evaluation. Sawston, Cambridge, 2022, pp. 435–459.Schmaier, A. H. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities / A. H. Schmaier // Thrombosis and Haemostasis. – 2016. – Vol. 14, N 1. – Р. 28–39. https://doi.org/10.1111/jth.13194Schmaier A. H. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. Thrombosis and Haemostasis, 2016, vol. 14, no. 1, pp. 28–39. https://doi.org/10.1111/jth.13194Liu, Y. In vitro hemocompatibility evaluation of poly (4-hydroxybutyrate) scaffold / Y. Liu // Journal of Clinical and Experimental Medicine. – 2014. – Vol. 7, N 5. – Р. 1233–1243.Liu Y. In vitro hemocompatibility evaluation of poly (4-hydroxybutyrate) scaffold. International. Journal of Clinical and Experimental Medicine, 2014, vol. 7, no. 5, pp. 1233–1243.Bai, M. Y. Preclinical studies of non-stick thin film metallic glass-coated syringe needles / M. Y. Bai, Y. C. Chang, J. P. Chu // Scientific Reports. – 2020. – Vol. 10, N 1. – Art. 20313. https://doi.org/10.1038/s41598-020-77008-yBai M. Y., Chang Y. C., Chu J. P. Preclinical studies of non-stick thin film metallic glass-coated syringe needles. Scientific Reports, 2020, vol. 10, no. 1, art. 20313. https://doi.org/10.1038/s41598-020-77008-yJaffer, I. H. The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem / I. H. Jaffer, J. I. Weitz // Acta Biomaterialia. – 2019. – Vol. 94. – P. 2–10. https://doi.org/10.1016/j.actbio.2019.06.021Jaffer I. H., Weitz J. I. The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem. Acta Biomaterialia, 2019, vol. 94, pp. 2–10. https://doi.org/10.1016/j.actbio.2019.06.021Braune, S. Developing standard and test protocols for testing the hemocompatibility of biomaterials / S. Braune, A. Lendlein, F. Jung // Hemocompatibility of biomaterials for clinical applications: blood – biomaterials interaction / ed. C. Siedlecki. – Duxford, United Kingdom, 2018. – P. 51–65.Braune S., Lendlein A., Jung F. Developing standard and test protocols for testing the hemocompatibility of biomaterials. Hemocompatibility of biomaterials for clinical applications: blood – biomaterials interaction. Duxford, UK, 2018, pp. 51–65.Hrynchak, V. A. Peculiarities of toxic effects produced by diisononyl phthalate and regulation over it in polymer materials and medical products / V. A. Hrynchak, S. I. Sychik // Health Risk Analysis. – 2020. – N 1. – P. 118–125. https://doi.org/10.21668/health.risk/2020.1.13.engHrynchak V. A., Sychik S. I. Peculiarities of toxic effects produced by diisononyl phthalate and regulation over it in polymer materials and medical products. Health Risk Analysis, 2020, no. 1, pp. 118–125. https://doi.org/10.21668/health.risk/2020.1.13.engExperimental models of animal chronic pathology in assessing health risks for sensitive population groups / E. V. Drozdova, S. I. Sychik, V. A. Hrynchak, S. N. Rjabceva // Health Risk Analysis. – 2022. – N 2. – P. 185–195. https://doi.org/10.21668/health.risk/2022.2.17.engDrozdova E. V., Sychik S. I., Hrynchak V. A., Rjabceva S. N. Experimental models of animal chronic pathology in assessing health risks for sensitive population groups. Health Risk Analysis, 2022, no. 2, pp. 185–195. https://doi.org/10.21668/health.risk/2022.2.17.engAn in vitro hemodynamic loop model to investigate the hemocytocompatibility and host cell activation of vascular medical devices / M. Wacker, U. Betke, K. Borucki [et al.] // Journal of Visualized Experiments. – 2020. – Vol. 162. – P. e61570. https://doi.org/10.3791/61570Wacker M., Betke U., Borucki K., Hülsmann J., Awad G., Varghese S., Scherner M., Hansen M., Wippermann J., Veluswamy P. An in vitro hemodynamic loop model to investigate the hemocytocompatibility and host cell activation of vascular medical devices. Journal of Visualized Experiments, 2020, vol. 162, p. e61570. https://doi.org/10.3791/61570Blok, L. J. S. Oeveren In vitro hemocompatibility testing: the importance of fresh blood / L. J. S. Blok, Engels G. E., W. van Oeveren // Biointerphases. – 2016. – Vol. 11. – P. 029802. https://doi.org/10.1116/1.4941850Blok L. J. S., Engels G. E., van Oeveren W. In vitro hemocompatibility testing: the importance of fresh blood. Biointerphases, 2016, vol. 11, p. 029802. https://doi.org/10.1116/1.4941850Sarode D. N., Roy S. In vitro models for thrombogenicity testing of blood-recirculating medical devices // Expert Review of Medical Devices. – 2019. – Vol. 16, N 7. – P. 603–616. https://doi.org/10.1080/17434440.2019.1627199Sarode D. N., Roy S. In vitro models for thrombogenicity testing of blood-recirculating medical devices. Expert Review of Medical Devices, 2019, vol. 16, no. 7, pp. 603–616. https://doi.org/10.1080/17434440.2019.1627199Gerwin, E. E. In vitro blood flow model with physiological wall shear stress for hemocompatibility testing – An example of coronary stent testing / E. E. Gerwin, L. J. B. Sjoerd, O. van Willem // Biointerphases. – 2016. – Vol. 11, N 3. – Art. 031004. https://doi.org/10.1116/1.4958979Gerwin E. E., Sjoerd L. J. B., van Willem O. In vitro blood flow model with physiological wall shear stress for hemocompatibility testing – An example of coronary stent testing. Biointerphases, 2016, vol. 11, no. 3, art. 031004. https://doi.org/10.1116/1.4958979Development and hemocompatibility testing of nitric oxide releasing polymers using a rabbit model of thrombogenicity / T. Major, H. Handa, G. Annich, R. Bartlett // Journal of Biomaterials. – 2014. – Vol. 29, N 4. – P. 479–501. https://doi.org/10.1177/0885328214538866Major T., Handa H., Annich G., Bartlett R. Development and hemocompatibility testing of nitric oxide releasing polymers using a rabbit model of thrombogenicity. Journal of Biomaterials, 2014, vol. 29, no. 4, pp. 479–501. https://doi.org/10.1177/0885328214538866van Kruchten, R. Measurement of whole blood thrombus formation using parallel-plate flow chambers – a practical guide / R. van Kruchten, J. M. Cosemans, J. W. Heemskerk // Platelets. – 2012. – Vol. 23, N 3. – P. 229–242. https://doi.org/10.3109/09537104.2011.630848van Kruchten R., Cosemans J. M., Heemskerk J. W. Measurement of whole blood thrombus formation using parallel-plate flow chambers – a practical guide. Platelets, 2012, vol. 23, no. 3, pp. 229–242. https://doi.org/10.3109/09537104.2011.630848Blood-contacting biomaterials: In vitro evaluation of the hemocompatibility / M. Weber, H. Steinle, S. Golombek [et al.] // Frontiers in Bioengineering and Biotechnology. – 2018. – Vol. 16, N 6. – Art. 99. https://doi.org/10.3389/fbioe.2018.00099Weber M., Steinle H., Golombek S., Hann L., Schlensak C., Wendel H. P., Avci-Adali M. Blood-contacting biomaterials: In vitro evaluation of the hemocompatibility. Frontiers in Bioengineering and Biotechnology, 2018, vol. 16, no. 6, art. 99. https://doi.org/10.3389/fbioe.2018.00099Contact system revisited: an interface between inflammation, coagulation, and innate immunity / A. T. Long, E. Kenne, R. Jung [et al.] // Journal of Thrombosis and Haemostasis. – 2016. – Vol. 14, N 3. – P. 427–437. https://doi.org/10.1111/jth.13235Long A. T., Kenne E., Jung R., Fuchs T. A., Renné T. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. Journal of Thrombosis and Haemostasis, 2016, vol. 14, no. 3, pp. 427–437. https://doi.org/10.1111/jth.13235Recent strategies for improving hemocompatibility and endothelialization of cardiovascular devices and inhibition of intimal hyperplasia / L.-A. Feng, J. Shi, J. Y. Guo, S.-F. Wang // Journal of Materials Chemistry B. – 2022. – Vol. 10, N 20. – P. 3781–3792. https://doi.org/10.1039/d2tb00478jFeng L.-A., Shi J., Guo J. Y., Wang S.-F. Recent strategies for improving hemocompatibility and endothelialization of cardiovascular devices and inhibition of intimal hyperplasia. Journal of Materials Chemistry B, 2022, vol. 10, no. 20, pp. 3781–3792. https://doi.org/10.1039/d2tb00478jAccelerated hemocompatibility testing of rotary blood pumps / A. P. McNamee, T. A. Griffith, A. G. Smith [et al.] // American Society for Artificial Internal Organs Journal. – 2023. – Vol. 69, N 10. – P. 918–923. https://doi.org/10.1097/MAT.0000000000001995McNamee A. P., Griffith T. A., Smith A. G., Kuck L., Simmonds M. J. Accelerated hemocompatibility testing of rotary blood pumps. American Society for Artificial Internal Organs Journal, 2023, vol. 69, no. 10, pp. 918–923. https://doi.org/10.1097/MAT.0000000000001995Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo / W. Y. Jonathan, A. R. Stafford, P. Liao [et al.] // Blood. – 2011. – Vol. 118, N 25. – P. 6667–6674. https://doi.org/10.1182/blood-2011-07-364141Jonathan W. Y., Stafford A. R., Liao P., Fredenburgh J. C., Roberts R., Weitz J. I. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Journal Blood, 2011, vol. 118, no. 25, pp. 6667–6674. https://doi.org/10.1182/blood-2011-07-364141

The authors declare that there are no conflicts of interest present.